Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Kína4. fázis

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS

A legfontosabb adatok

Ki végzi
Peking Union Medical College
Hol
Nanjing (Kína)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
30 fő, tervezett
Kezdés
2025. dec. 1.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Topical injection of Secukinmab
  • Subcutaneous injection of Secukinumab
A regiszteradat frissítve
2025. december 3.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with hidradenitis suppurativa (HS), a long-term skin disease with painful lumps. Their lesions must be in only one body area and not helped by usual treatment.

Életkor
18 years or older
Nem
All sexes
A betegség stádiuma
HS for at least 6 months, with lesions limited to a single body area.
Korábbi kezelés
Usual treatment did not clearly help for at least 3 months. No biologics, immunosuppressants or systemic corticosteroids in the last 3 months.

A részvétel fő kizáró okai

  • Allergy to any part of the secukinumab injection
  • Severe failure of a vital organ
  • Active infection, or cancer in the past 5 years (except treated basal or squamous cell skin cancer)
  • Pregnant, breastfeeding or planning a pregnancy during the study
  • Mental disorder or memory and thinking problems that prevent understanding the study

A regiszter feltételei, szó szerint

Mind a 13 feltétel megnézéseKevesebb

Ki vehet részt

  • Meet international diagnostic criteria for hidradenitis suppurativa
  • Aged ≥ 18 years
  • Disease duration ≥ 6 months and resistance to conventional therapy (no significant improvement for ≥ 3 months)
  • Lesions were confined to a single anatomical area
  • Voluntarily signed the informed consent form and was able to cooperate in all visits and examinations

Ki nem vehet részt

  • Treatment with biologics, immunosuppressants, or systemic corticosteroids within the last 3 months
  • Participating in another clinical study and are at risk of an interaction between the study drugs
  • Hypersensitivity to any component of secukinumab injection
  • With severe vital organ failure
  • With active infection or malignancy (malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin and cured)
  • Mental disorders or cognitive impairment that precludes understanding of study procedures
  • Other conditions assessed by the investigators as inappropriate for participation in the study
  • Pregnant, nursing, or planning conception during the study

Helyszínek itt: Kína

  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing, Jiangsu 210042Nanjing, KínaContact: Junyou ZHENG, DrToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Secukinumab is currently approved in Europe, US and China for the treatment of moderate to severe HS as a biologic agent targeting IL-17A.Two phase III clinical trials (SUNSHINE and SUNRISE) showed that 300 mg s.c. every 2 weeks resulted in 42% to 45% of patients achieving a clinical response (HiSCR) to HS, and the efficacy was sustained through 52 weeks.However, we found in clinical practice that some HS patients present with localized lesions (small areas of involvement, affecting only 1-2 anatomic areas) that are resistant to conventional therapy, and have not yet fulfilled surgical indications, and the need for systemic biologic therapy is controversial.Such patients often experience inadequate response or slow onset of action when they receive secukinumab by routine subcutaneous injection - possibly related to inadequate drug concentration in the focal lesional area and limited local anti-inflammatory effects after systemic administration.In addition, side effects of conventional subcutaneous injection system are greater, and the application is limited in some patients, so it is necessary to explore more appropriate and safer drug delivery method for localized skin lesions.Localized HS, local injection of lesions may enhance anti-inflammatory effects while reducing systemic exposure by increasing drug concentrations at the lesion site.Therefore, exploring novel modes of administration of secukinumab has practical clinical implications based on clinical practice needs and the context of the previous literature.In summary, by exploring the efficacy and safety of local skin injection of secukinumab, this study may provide a new strategy for the treatment of limited HS with sufficient scientific rationale and significant potential benefits and manageable risks.

A vizsgálat 2 csoportja

  • Topical injectionA vizsgált kezelés

    Kezelés: Topical injection of Secukinmab

  • Subcutaneous injectionMár használt kezelés, összehasonlításként

    Kezelés: Subcutaneous injection of Secukinumab

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Comparison of the Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS: A Prospective Exploratory Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. december 3.